Combining PET/CT with serum tumor markers to improve the evaluation of histological type of suspicious lung cancers

PLoS ONE

Volumn 12, Issue 9, 2017, Pages

  Jiang, Rifeng ^a,b   Dong, Ximin ^b   Zhu, Wenzhen ^a   Duan, Qing ^b   Xue, Yunjing ^b   Shen, Yanxia ^a   Zhang, Guopeng ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; FLUORODEOXYGLUCOSE F 18; NEURON SPECIFIC ENOLASE; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; ARTICLE; BLOOD LEVEL; CANCER CLASSIFICATION; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SMALL CELL LUNG CANCER; SQUAMOUS CELL LUNG CARCINOMA; AGED; AREA UNDER THE CURVE; BLOOD; DIAGNOSTIC IMAGING; DNA MUTATIONAL ANALYSIS; IMAGE PROCESSING; LUNG TUMOR; MIDDLE AGED; MUTATION; REGRESSION ANALYSIS; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AREA UNDER CURVE; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; RECEPTOR, EPIDERMAL GROWTH FACTOR; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA;

EID: 85029052631     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0184338     Document Type: Article

References (30)

1. Nurwidya F, Takahashi F, Takahashi K. Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation. Journal of natural science, biology, and medicine. 2016; 7(2):119–23. Epub 2016/07/20. https://doi.org/10.4103/0976-9668.184695 PMID: 27433059; PubMed Central PMCID: PMC4934098.
2. Ferrell B, Koczywas M, Grannis F, Harrington A. Palliative care in lung cancer. The Surgical clinics of North America. 2011; 91(2):403–17, ix. Epub 2011/03/23. https://doi.org/10.1016/j.suc.2010.12.003 PMID: 21419260; PubMed Central PMCID: PMC3655433.
3. Herbst RS, Heymach JV, Lippman SM. Lung cancer. The New England journal of medicine. 2008; 359 (13):1367–80. Epub 2008/09/26. https://doi.org/10.1056/NEJMra0802714 PMID: 18815398.
4. Sun S, Schiller JH, Spinola M, Minna JD. New molecularly targeted therapies for lung cancer. The Journal of clinical investigation. 2007; 117(10):2740–50. Epub 2007/10/03. https://doi.org/10.1172/ JCI31809 PMID: 17909619; PubMed Central PMCID: PMC1994616.
5. Cortinovis D, Abbate M, Bidoli P, Capici S, Canova S. Targeted therapies and immunotherapy in nonsmall-cell lung cancer. Ecancermedicalscience. 2016; 10:648. Epub 2016/07/20. https://doi.org/10.3332/ecancer.2016.648 PMID: 27433281; PubMed Central PMCID: PMC4929979.
6. Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2008; 21 Suppl 2:S16–22. Epub 2008/06/24. https://doi.org/10.1038/modpathol.3801018 PMID: 18437168.
7. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England journal of medicine. 2004; 350(21):2129–39. Epub 2004/05/01. https://doi.org/10.1056/NEJMoa040938 PMID: 15118073.
8. Johnson BE, Janne PA. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer research. 2005; 65(17):7525–9. Epub 2005/09/06. https://doi.org/10.1158/0008-5472. CAN-05-1257 PMID: 16140912.
9. Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: diagnosis and management. American family physician. 2007; 75(1):56–63. Epub 2007/01/18. PMID: 17225705.
10. Ko KH, Hsu HH, Huang TW, Gao HW, Shen DH, Chang WC, et al. Value of (1)(8)F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma. European journal of nuclear medicine and molecular imaging. 2014; 41(10):1889–97. Epub 2014/05/24. https://doi.org/10.1007/s00259-014-2802-y PMID: 24852187.
11. Higashi K, Ueda Y Fau—Arisaka Y, Arisaka Y Fau—Sakuma T, Sakuma T Fau—Nambu Y, Nambu Y Fau—Oguchi M, Oguchi M Fau—Seki H, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med. 2002; 1(43):39–45.
12. Aquino SL, Halpern EF, Kuester LB, Fischman AJ. FDG-PET and CT features of non-small cell lung cancer based on tumor type. International journal of molecular medicine. 2007; 19(3):495–9. Epub 2007/02/03. PMID: 17273799.
13. de Geus-Oei LF, van Krieken JH, Aliredjo RP, Krabbe PF, Frielink C, Verhagen AF, et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer. 2007; 55(1):79–87. Epub 2006/10/19. https://doi.org/10.1016/j.lungcan.2006.08.018 PMID: 17046099.
14. Liu LP, Zhang XX, Cui LB, Li J, Yang JL, Yang HN, et al. Preliminary comparison of diffusion-weighted MRI and PET/CT in predicting histological type and malignancy of lung cancer. The clinical respiratory journal. 2015. Epub 2015/04/29. https://doi.org/10.1111/crj.12316 PMID: 25918835.
15. Molina R, Auge JM, Escudero JM, Marrades R, Vinolas N, Carcereny E, et al. Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21–1, CEA, SCC and NSE. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2008; 29(6):371–80. Epub 2008/12/09. https://doi.org/10.1159/000181180 PMID: 19060513.
16. Molina R, Auge JM, Bosch X, Escudero JM, Vinolas N, Marrades R, et al. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2009; 30(3):121–9. Epub 2009/06/10. https://doi.org/10.1159/000224628 PMID: 19506400.
17. Walker SH, Duncan DB. Estimation of the Probability of an Event as a Function of Several Independent Variables. Biometrika. 1967; 54(1/2):167. https://doi.org/10.2307/2333860
18. Suzawa N, Ito M, Qiao S, Uchida K, Takao M, Yamada T, et al. Assessment of factors influencing FDG uptake in non-small cell lung cancer on PET/CT by investigating histological differences in expression of glucose transporters 1 and 3 and tumour size. Lung Cancer. 2011; 72(2):191–8. Epub 2010/10/05. https://doi.org/10.1016/j.lungcan.2010.08.017 PMID: 20884076.
19. Deppen SA, Blume JD, Kensinger CD, Morgan AM, Aldrich MC, Massion PP, et al. Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis. Jama. 2014; 312 (12):1227–36. Epub 2014/09/24. https://doi.org/10.1001/jama.2014.11488 PMID: 25247519; PubMed Central PMCID: PMC4315183.
20. Shi P, Meng X, Ni M, Sun X, Xing L, Yu J. Association between serum tumor markers and metabolic tumor volume or total lesion glycolysis in patients with recurrent small cell lung cancer. Oncology letters. 2015; 10(5):3123–8. Epub 2016/01/02. https://doi.org/10.3892/ol.2015.3673 PMID: 26722299; PubMed Central PMCID: PMC4665208.
21. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. Journal of the National Cancer Institute. 2005; 97(5):339–46. Epub 2005/03/03. https://doi.org/10.1093/jnci/dji055 PMID: 15741570.
22. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25(5):587–95. Epub 2007/02/10. https://doi.org/10.1200/JCO.2006.07.3585 PMID: 17290067.
23. Huang CT, Yen RF, Cheng MF, Hsu YC, Wei PF, Tsai YJ, et al. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Med Oncol. 2010; 27(1):9–15. Epub 2009/01/09. https://doi.org/10.1007/s12032-008-9160-1 PMID: 19130320.
24. Na II, Byun BH, Kim KM, Cheon GJ, Choe du H, Koh JS, et al. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis. Lung Cancer. 2010; 67(1):76–80. Epub 2009/04/18. https://doi.org/10.1016/j.lungcan.2009.03.010 PMID: 19371962.
25. Mak RH, Digumarthy SR, Muzikansky A, Engelman JA, Shepard JA, Choi NC, et al. Role of 18F-fluoro-deoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. The oncologist. 2011; 16(3):319–26. Epub 2011/02/23. https://doi.org/10.1634/theoncologist.2010-0300 PMID: 21339258; PubMed Central PMCID: PMC3228101.
26. Shoji F, Yoshino I, Yano T, Kometani T, Ohba T, Kouso H, et al. Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. Cancer. 2007; 110(12):2793–8. Epub 2007/10/18. https://doi.org/10.1002/cncr.23101 PMID: 17941001.
27. Kamiya A, Murayama S, Kamiya H, Yamashiro T, Oshiro Y, Tanaka N. Kurtosis and skewness assessments of solid lung nodule density histograms: differentiating malignant from benign nodules on CT. Japanese journal of radiology. 2014; 32(1):14–21. Epub 2013/11/20. https://doi.org/10.1007/s11604-013-0264-y PMID: 24248771.
28. Kido S, Kuriyama K, Higashiyama M, Kasugai T, Kuroda C. Fractal Analysis of Small Peripheral Pulmonary Nodules in Thin-section CT: Evaluation of the Lung-nodule Interfaces. Journal of Computer Assisted Tomography. 2002; 26(4):573–8. https://doi.org/10.1097/00004728-200207000-00017 PMID: 12218822
29. Chae HD, Park CM, Park SJ, Lee SM, Kim KG, Goo JM. Computerized texture analysis of persistent part-solid ground-glass nodules: differentiation of preinvasive lesions from invasive pulmonary adenocarcinomas. Radiology. 2014; 273(1):285–93. Epub 2014/08/08. https://doi.org/10.1148/radiol.14132187 PMID: 25102296.
30. Kim DH, Jung JH, Son SH, Kim CY, Hong CM, Oh JR, et al. Prognostic Significance of Intratumoral Metabolic Heterogeneity on 18F-FDG PET/CT in Pathological N0 Non-Small Cell Lung Cancer. Clinical nuclear medicine. 2015; 40(9):708–14. Epub 2015/06/23. https://doi.org/10.1097/RLU. 0000000000000867 PMID: 26098287.